1,167 subjects participated in a 24-week blinded, randomized controlled trial to assess the impact of pharmacogenomic treatment response compared to the usual “Trial & Error” treatment response.
165 subjects participated in an 8-week study that compared symptoms experienced during treatment guided by pharmacogenomic testing to the usual unguided treatment.
49 subjects participated in a 10-week blinded, randomized controlled that compared pharmacogenomic-guided treatment to with the usual “Trial & Error” treatment.
44 subjects participated in an 8-week study that compared pharmacogenomic treatment to unguided “Trial & Error” treatment.
Over the course of 1 year, pharmacy claims were compared between patients with pharmacogenomic-based treatment and a control group.